ISPOR 7th ANNUAL EUROPEAN CONGRESS
Medical Device & Diagnostics Forum
26 October 2004
CCH Congress Centrum Hamburg, Hamburg, Germany
HOSPITAL COSTING OF MEDICAL DEVICE THERAPY IN THE DRG ENVIRONMENT
Jenifer Ehreth PhD, Director Reimbursement and Government Affairs, Medtronic Europe, Tolochenaz, Switzerland
Increasingly European health care systems are switching to a Diagnosis-Related Group (DRG) based hospital financing system. Even though the rational to introduce DRG based financing systems may differ between the countries all variations of DRG systems do share a common set of features. The introduction of DRGs in Europe will create new challenges and opportunities for providers and purchasers of health care and the health care industry. Europe will best benefit form DRGs if they are willing to learn form countries with a DRG history such as the United States.
Impact of DRGs on the Introduction of New Technologies - Experience from the United States
Speaker: Deborah Williams MS, United States House of Representatives, Ways and Means Subcommittee on Health, Director, House Office, Washington, DC, USA
Experiences in the United States with mechanisms to encourage the adoption of new technology in the Diagnosis-Related Group (DRG) environment will be presented. Both the hospital and the United States government perspectives will be presented.
Hospital Incentives under a DRG System – European Perspectives
Speaker: Karl-Peter Pfeiffer MD, Professor, University of Innsbruck, Innsbruck, Austria
Many countries in Europe are implementing DRGs into their health care system. Challenges in providing hospital incentives as well as mechanisms to stimulate adoption of innovation under a DRG system will be discussed.
ISPOR 6th ANNUAL EUROPEAN CCONGRESS
Medical Device & Diagnostics Forum
10 November 2003
Princesa Sofia InterContinental, Barcelona, Spain
DIAGNOSTICS TESTING PROVIDES ACTIONABLE INFORMATION ACTUAL VALUE VERSUS PERCEIVED VALUE: ARE THERE ANY DISCREPENCIES?
Moderator: Markus Siebert MS, Chair: ISPOR Medical Devices & Diagnostics Council and Director, EUCOMED, Brussels, Belgium
Tuberculosis as a Case Study
Speaker: Knut Feldmann MD, PhD, PhD, Professor, ASKLEPIOS Fachkliniken, München-Gauting, Institut für Laboratoriumsdiagnostik, Gauting, Germany
The need for screening can be described by objective indicators such as incidence and dynamics of the spread. The objective need for screening in well-defined groups is not well perceived. Financial aspects only determine the policy. Priority setting is determined by other factors as well. The decision-making process has to be challenged. These issues will be discussed using tuberculosis as case study.
Barriers to Screening Program Implementations
Speaker: Helmut Wenzel PhD, Helmut Wenzel PhD, Roche Diagnostics GmbH, Applied Health Economics & Outcomes Research, Mannheim, Germany
Data on the value of diagnostics are necessary but not sufficient for reimbur¬sement. A key issue is the definition of the risk group that should be subject to screening. Policymaking is determined by many factors and varies by country. Screening program policies reflect perceived needs, options and constraints (see diagram above). Screening program decisions are to be made when the epidemiological and medical needs and benefits, as well as economic constraints are met (within the inter¬sec¬tion of the overlapping circles). Health care goals are defined depending on the overall national policies and priorities. For example, for toxoplasmosis, if family policy is the very focus of government, screening for toxoplasmosis is offered to every pregnant woman such as in France. If finan¬cing is the issue, then family policy may be overruled by financial constraints; and the test will be offered to a limited group of pregnant women. These issues will be discussed during this presentation.
ISPOR 5th ANNUAL EUROPEAN CONGRESS
Medical Device & Diagnostics Forum
3 November 2002
De Doelen Congress Center, Rotterdam, The Netherlands
BASING MEDICAL DEVICES AND DIAGNOSTIC REIMBURSEMENT POLICIES ON ECONOMIC AND CLINICAL
INFORMATION: HOW TO INCORPORATE TOTAL HEALTHCARE COSTS AND OUTCOMES
Moderator: Markus Siebert MSc, Business Area Director - Economic Affairs, Eucomed, Brussels,Belgium
Total Healthcare Costs and Outcomes: Thoughts on the 5th and 6th Hurdle on the Way to Coverage Of Medical Technology
Rod Taylor PhD, Department Of Public Health And Epidemiology, The University Of Birmingham, Birmingham, UK
Systematic Assessment of Health Technologies, Outcomes Research, and Technological Competitiveness: A Conceptual Model For Transparent "Rules of the Game" as a Basis for Reimbursement Policies in Health Care Systems
Speaker Dr. Jose A Valverde, Director, Agencia de Evaluacion
de Tecnologias Sanitarias de Andalucia (Spanish Agency for Health Technology
Assessment), Seville, Spain
The Impact of ‘Silo’ Budgets on Health System Performance: The Industry Experience
Speaker: Arne Heissel PhD, Health Outcomes Manager-Europe, Ethicon Endo-Surgery, Norderstedt, Germany and Brigitte Casteels, Therapy Access Manager-Neurological Division, Medtronic Europe SA, Suisse, Belgium
ISPOR 4th ANNUAL EUROPEAN CONGRESS
Medical Device & Diagnostics Forum
11 November 2001
Noga Hilton Cannes, Cannes, France
THE EVOLUTION OF ECONOMIC EVALUATIONS AND OUTCOMES RESEARCH FOR MEDICAL DEVICES IN EUROPE
How and Why the Medical Device Industry Is Focusing on Outcomes Research and Economic Evaluations
Speaker: Markus Siebert MS, Business Area Director-Economic Affairs, EUCOMED, Brussels, Belgium
The establishment of NICE is the most visible illustration of an increased use of economic evaluation for decision-making on coverage and funding for healthcare. This presentation will review the situation of the medical devices industry in Europe: what has changed with the appearance of NICE? What is the situation in other European countries and what is the going on at European level? Further, an overview will be provided on the recent activities on economic evaluation and HTA conducted by Eucomed, the European trade association in the field of medical devices. Underlying tenor of these activities is that medical devices require a recognition of a number of specifics that make them different from pharmaceuticals and hence an accordingly tailored approach to economic evaluation and outcomes research. The presentation will show that the medical devices industry in Europe is not opposed to HTA and economic evaluation and acknowledges their potential to rationalise decision-making in healthcare. However, it is essential that these processes are commensurate with the requirements of an innovative and fast-moving medical devices industry in Europe and do not obstruct patient access to innovative medical technologies.
Healthcare Insurers’ Use of Outcomes Research and Economic Evaluations
Patrick Galloo MD, Socialistische Mutualiteiten, Brussels, Belgium
The evolution of the almost uncontrollable sickness insurance expenditure has urged the policymakers all over the western world to pay more attention to the medical as well as economic evaluation of new services. The increase of healthcare expenditures is present all over the world, but varies considerably from one country to another. Evidence-based medicine, scenario analysis and management accounting have become current expressions that are often used before a new technique will or will not be reimbursed. This presentation will focus on the subject of compulsory insurance. The initiatives accomplished in this field by the government or the sickness funds in Belgium are comparable with those taken by private insurances in other countries. For the past two years, thanks to the revival of the economy, new techniques are becoming more available in our compulsory system. However, these new techniques are subject to economic and medical restrictions. On the basis of a number of examples, the different methods that may be used to measure the efficiency and economic relevance will be discussed. Furthermore, it will be explained which partners play a role in this process. This will give us some idea how new techniques can be introduced, taking into consideration the different partners, budgets and sensitivities of different sectors.
Integrating Economic Evaluations into Reimbursement Negotiations
Volker Kruse, Director, Ethicon Endo-Surgery (Europe), Norderstedt, Germany
Creating economic evaluations of products and procedures does not have a history in Medical Device and Diagnostic (MD&D) companies. NICE in the UK was the first institution requesting data to demonstrate the economic and clinical value of a new product, procedure or surgical technique. For almost four years now certain MD&D companies are working on the development of health economic resources and on the internal and external process, to be prepared for the future.
Two important components are key for success: On one hand a well-established and good working network of European and local Health Economic Outcomes Experts, and on the other hand a convincing value proposition. This value proposition consists of a clear understanding of market and customer (all stakeholders, including the patient) needs, the clinical benefits, the economic evidence as well as an optimal price, balancing between the value and whether it fits into the various reimbursement systems. The research triangle covering market- (including price-), clinical- and economic research provides the value proposition.
Apart from different Health Care Systems, the type of economic evaluation is similar. This provides the opportunity to create economic models, train the different stakeholders on their usage and support each country on their local reimbursement negotiations. A situation like this requests processes, best practice (sharing) and a forum to establish rules.
Apart from different Health Care Systems, the type of economic evaluation is similar. This provides the opportunity to create economic models, train the different stakeholders on their usage and support each country on their local reimbursement negotiations. A situation like this requests processes, best practice (sharing) and a forum to establish rules blinded etc. clinical and economic trials. As these are key components, the culture inside MD& D companies is changing.
presentation will guide you through this process and will show examples of a
successful integration of economic evaluations into reimbursement
Back to main page